Overview
- Reporting from multiple outlets said the WTA updated its eligibility policy on Sunday to require a one-time genetic test that checks for the SRY gene as a condition to compete on the tour.
- The WTA’s new rule allows the test to be done by a cheek swab or blood sample and says players who refuse or who test positive may face disciplinary measures and temporary ineligibility.
- The policy marks a clear shift from the prior approach that let transgender women compete after declaring female identity and maintaining lowered testosterone through ongoing monitoring.
- Advocates warn the rule raises privacy and reputational risks because the policy fragment ties refusal or ineligibility to possible public disclosure, while supporters say it targets both transgender athletes and rare differences of sex development.
- The move follows similar actions by some sports bodies and could prompt legal challenges and broader debate over fairness, medical science, and data protection for athletes on the women’s tour.